Relfovetmab

Osteoarthritis-related pain in cats^[1]

0.5-1.25 mg/kg; 2.5 mg (1.0 mL of 2.5 mg/mL) for 2.1-5.0 kg; 6.4 mg (1.0 mL of 6.4 mg/mL) for 5.1-12.8 kg

s.c.; every three months; Days 0, 90, and 180

On Day 90, 73.0% of cats achieved response success, defined as a ≥2 reduction from baseline in TCSOM score and no increase in any individual CSOM activity score.
Mean percentage reduction in TCSOM scores from pretreatment was up to 62.6% during the study.
A greater proportion of cats achieved CSOM response success throughout Days 3-270 when success was defined by ≥3, ≥4, or ≥5 score improvement.
Caregiver overall assessment showed a greater percentage of cats with “excellent” or “good” response at every assessment point, starting Day 3.
Quality of life assessment showed a greater percentage of cats rated “greatly improved” or “slightly improved” at every assessment point; temperament showed similar results; happiness assessment showed a greater percentage rated “much happier” or “slightly happier” throughout the study, with caregiver assessments showing responses as early as three days after the first administration.
VCA response success ranged from 62.6% to 81.2% across post-dose visits.
At baseline, 60.1% of cats had severe pain (score 3) and 11.1% were nearly incapacitated (score 4); at Day 270, 15.7% had severe pain and 0.8% were nearly incapacitated.
Six cats (3.9%) were withdrawn for lack of efficacy.